Shares of ProMetic Life Sciences Inc. (TSE:PLI) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is C$4.84.

PLI has been the subject of several analyst reports. CIBC dropped their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Canaccord Genuity upped their target price on ProMetic Life Sciences from C$4.50 to C$4.75 and gave the company a “buy” rating in a research note on Friday. Bloom Burton reiterated a “hold” rating on shares of ProMetic Life Sciences in a research note on Thursday, October 13th. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday, August 25th. Finally, Scotiabank reissued an “outperform” rating and set a C$5.00 price target on shares of ProMetic Life Sciences in a research report on Tuesday, August 16th.

Shares of ProMetic Life Sciences (TSE:PLI) opened at 2.83 on Thursday. The stock’s 50 day moving average price is $2.89 and its 200 day moving average price is $2.94. ProMetic Life Sciences has a 12 month low of $1.88 and a 12 month high of $3.62. The firm’s market cap is $1.71 billion.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.